HITEC 2026: Revinate's Ivy automates up to 80% of routine guest inquiries
Revinate debuted Ivy at HITEC 2026, a decision-intelligence layer that automates up to 80% of routine guest inquiries across its platform.
Real insight from the people actually doing the work: operators, engineers, and leaders across 16 B2B industries.
ABB says 2026 marks a turning point for smart buildings, where interoperable systems and reliable data infrastructure become non-negotiable for AI to function.
Smart IoT-enabled buildings are projected to reach 115 million globally by 2026, as the broader market surges from $141.79B to $554B by 2033.
77% of professionals expect agentic AI to be central to their workflow by 2030, yet only 18% of organizations currently measure its ROI.
Quotient Sciences has dosed patients in a Phase I trial it describes as the first AI-formulated drug to reach clinical evaluation.
Get started
Book a 15-minute demo and we will map your experts to the content your market is searching for.
Or call us. No forms required. We pick up. 214-945-2512
The best thinking on B2B industries and the future of how markets communicate, delivered every Tuesday.
Join 3,000+ B2B marketing leaders. Unsubscribe any time.
Free workspace
These stories come from MarketScale. Create a free workspace and turn your own team's expertise into published media that buyers and AI engines actually cite. No credit card, no demo required.
Real insight from the people actually doing the work: operators, engineers, and leaders across 16 B2B industries.
ABB says 2026 marks a turning point for smart buildings, where interoperable systems and reliable data infrastructure become non-negotiable for AI to function.
Smart IoT-enabled buildings are projected to reach 115 million globally by 2026, as the broader market surges from $141.79B to $554B by 2033.
77% of professionals expect agentic AI to be central to their workflow by 2030, yet only 18% of organizations currently measure its ROI.
Quotient Sciences has dosed patients in a Phase I trial it describes as the first AI-formulated drug to reach clinical evaluation.
Get started
Book a 15-minute demo and we will map your experts to the content your market is searching for.
Or call us. No forms required. We pick up. 214-945-2512
The best thinking on B2B industries and the future of how markets communicate, delivered every Tuesday.
Join 3,000+ B2B marketing leaders. Unsubscribe any time.